As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.

Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.

Japanese firm creates new US-based global organization that reaffirms strategic focus on oncology as main pillar of mid-term growth.

Highlights from complete response letter news from the Pink Sheet’s US FDA Performance Tracker.